The Texas company Orthofix recently announced their new bone growth stimulators have secured both U.S. Food and Drug Administration (FDA) clearance and European CE Mark approval. The devices are meant for patients recovering from spinal fusion surgery.
The SpinalStim and the CervicalStim deliver a low-level pulsed electromagnetic field (PEMF) to the patient. The PEMF is meant to kick-start the body’s natural healing process, promoting bone growth and strengthening. The new devices are the latest offerings in a broad line of bone growth stimulation systems that Orthofix inaugurated with the original SpinalStim in 1990.
While the noninvasive, out-of-the-office treatment option has an obvious appeal, the necessary patient compliance can be worrying for physicians. With that in mind, Orthofix has developed a mobile app called Stim onTrack. Besides the expected array of alerts and timelines for patients, the app delivers real-time data to physicians, detailing how effectively the patient is following the treatment protocol.
“Patient recovery is often dependent on how well they follow the prescription for the device,” explains James Ryaby, PhD, the chief scientific officer at Orthofix. “Equipping patients with a mobile app to help them adhere to their prescription is an excellent addition to this system while simultaneously enhancing post-surgical care by giving physicians additional data to help personalize follow-up protocols.”
Stim onTrack is available free of charge through the iTunes app store.